Stallion Remedies Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 16-11-2024
- Paid Up Capital ₹ 0.45 M
as on 16-11-2024
- Company Age 31 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 11.81%
(FY 2023)
- Profit -152.25%
(FY 2023)
- Ebitda -122.63%
(FY 2023)
- Net Worth -11.74%
(FY 2023)
- Total Assets -9.45%
(FY 2023)
About Stallion Remedies
The Corporate was formerly known as Stallion Dyestuffs Pvt Ltd. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.45 M, as per Ministry of Corporate Affairs (MCA) records.
Nita Mahajan, Rachana Nadkarni, Harish Mahajan, and One other member serve as directors at the Company.
- CIN/LLPIN
U24220MH1993PTC072437
- Company No.
072437
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Jun 1993
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Stallion Remedies?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vikrant Gaitonde  | Director | 08-May-2022 | Current |
| Nita Mahajan | Director | 17-Jun-1993 | Current |
| Rachana Nadkarni | Additional Director | 26-Apr-2024 | Current |
| Harish Mahajan | Director | 08-May-2022 | Current |
Financial Performance and Corporate Structure Insights of Stallion Remedies.
Stallion Remedies Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 11.81% increase. The company also saw a substantial fall in profitability, with a 152.25% decrease in profit. The company's net worth observed a substantial decline by a decrease of 11.74%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Stallion Remedies?
In 2023, Stallion Remedies had a promoter holding of 49.76% and a public holding of 50.24%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Retort Chemicals Private LimitedActive 50 years 10 monthsRachana Nadkarni, Harish Mahajan and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Stallion Remedies?
Stallion Remedies has a workforce of 12 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Stallion Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Stallion Remedies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
